Objective: To develop an evidence-based guideline for the pharmacologic and
nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the …

Objective: To develop comprehensive recommendations for the treatment of the various
clinical manifestations of psoriatic arthritis (PsA) based on evidence obtained from a …

Since the second version of the Group for Research and Assessment of Psoriasis and
Psoriatic Arthritis (GRAPPA) treatment recommendations were published in 2015 …

Background Etanercept, a tumour-necrosis-factor inhibitor, has shown efficacy in the
treatment of rheumatoid arthritis. Psoriatic arthritis and psoriasis are disease states in which …

Background: In a phase II study, etanercept (recombinant human tumor necrosis factor
receptor [p75]: Fc fusion protein) safely produced rapid, dose-dependent improvement in …

Objectives The provisional criteria of the American College of Rheumatology (ACR) 2010
and the 2011 self-report modification for survey and clinical research are widely used for …

Objective Adalimumab, a fully human, anti–tumor necrosis factor monoclonal antibody, was
evaluated for its safety and efficacy compared with placebo in the treatment of active …

Objective Etanercept has been shown to improve the articular and cutaneous manifestations
of psoriatic arthritis (PsA). In this study, we further evaluated the safety, efficacy, and effect on …

Objective To update the 2009 Group for Research and Assessment of Psoriasis and
Psoriatic Arthritis (GRAPPA) treatment recommendations for the spectrum of manifestations …

Objective Fibromyalgia syndrome (FMS) is characterized by widespread musculoskeletal
pain and lowered pain threshold. Other prominent symptoms include disordered sleep and …